| |
Study 1222.39
(n=108) |
Study 1222.40
(n=122) |
| Male, n (%) |
83 (76.9) |
75 (61.5) |
| Age, mean (SD), years |
61.7 (8.8) |
62.7 (7.9) |
| COPD diagnosis, mean (SD), years |
9.4 (8.1) |
9.3 (8.1) |
| Pre-bronchodilator |
|
|
| Mean (SD) FEV1, L |
1.483 (0.532) |
1.233 (0.489) |
| Post-bronchodilator |
|
|
| Mean (SD) FEV1, L |
1.656 (0.527) |
1.456 (0.516) |
| Mean (SD) FEV1 change from |
|
|
| pre-bronchodilator, L |
0.181 (0.162) |
0.223 (0.152) |
| Mean (SD) FEV1/FVC, % |
48.1 (11.7) |
45.5 (11.1) |
| Mean (SD) % of predicted normal FEV1 |
56.4 (15.2) |
50.5 (14.2) |
| GOLD, n (%) |
|
|
| 2 |
69 (63.9) |
63 (51.6) |
| 3 |
32 (29.6) |
48 (39.3) |
| 4 |
5 (4.6) |
11 (9.0) |
| Body mass index, mean (SD), kg/m2 |
27.5 (4.4) |
27.0 (6.3) |
| Current smoker, n (%) |
46 (42.6) |
66 (54.1) |
| Smoking history, mean (SD), pack-years |
41.5 (19.3) |
47.4 (23.5) |
| Baseline pulmonary medications |
|
|
| Any pulmonary medication, n (%) |
86 (79.6) |
106 (86.9) |
| SAMA,a n (%) |
14 (13.0) |
17 (13.9) |
| LAMAb (tiotropium), n (%) |
42 (38.9) |
51 (41.8) |
| SABAc (inhaled), n (%) |
62 (57.4) |
74 (60.7) |
| LABAb (inhaled), n (%) |
52 (48.1) |
66 (54.1) |
| Steroids, n (%) |
|
|
| Inhaledd |
50 (46.3) |
63 (51.6) |
| Orald |
1 (0.9) |
4 (3.3) |
| Xanthinesd, n (%) |
9 (8.3) |
7 (5.7) |
|
